

Clinical Policy: Oxycodone SR (Oxycontin)

Reference Number: CA.PPA.04

Effective Date: 07/18

Last Review Date: 10/18

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Oxycodone (Oxycontin[®]) is an opioid agonist.

FDA approved indication

Oxycontin is indicated for pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in:

- Adults
- Opioid tolerant pediatric patients 11 years of age and older who are already receiving and tolerate a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent.

Limitation of use:

- Because of the risks of addiction, abuse and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release formulations, reserve Oxycontin for use in patients for whom alternative treatment options (e.g. non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
- Oxycontin is not indicated as an as-needed (prn) analgesic.

Policy/Criteria

** Provider must submit documentation (including office chart notes and lab results) supporting that member has met all approval criteria **

It is the policy of California Health & Wellness and Health Net that Oxycontin is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Chronic Pain (must meet all):

1. Diagnosis of chronic pain;
2. Member must meet one of the following (a or b):
 - a. Age \geq 18 years;
 - b. Age \geq 11 years already receiving and tolerant to a minimum daily opioid dose of at least 20 mg immediate-release oxycodone or equivalent;
3. Failure of 1 PDL long acting narcotic analgesics, in combination with short-acting narcotic analgesics for break-through pain, unless member experiences clinically

CLINICAL POLICY

Oxycodone



significant adverse effects or has contraindication(s) to all PDL long acting narcotic analgesics;

4. Request does not exceed 2 tablets per day.

Approval duration: 6 months

- B.** Other diagnoses/indications – Refer to CP.PMN.53 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized)

II. Continued Therapy

A. Chronic Pain (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Request does not exceed 2 tablets per day;
3. Responding positively to therapy.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy; or
2. Refer to CP.PMN.53 if requested indication is NOT listed under section III (Diagnoses/Indications for which coverage is NOT authorized)

Approval duration: 12 months

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy - CP.PMN.53 or evidence of coverage documents

IV. Appendices/General Information

Appendix A: Abbreviation Key

FDA: Food and Drug Administration

PDL: preferred drug list

PRN: as needed

V. Dosage and Administration

Population	Recommended Initial Dose
Adults	10 mg tablets orally every 12 hours
Pediatric patients \geq 11 years	20 mg total daily dose

CLINICAL POLICY

Oxycodone



Geriatric patients	1/3 to 1/2 the recommended starting dosage
Patients with hepatic impairment	1/3 to 1/2 the recommended starting dosage

VI. Product Availability

Extended-release tablets: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, and 80 mg

VII. References

1. Oxycontin Prescribing Information. Stamford, CT. Purdue Pharma L.P.; August 2015. Available at: <http://app.purduepharma.com/xmlpublishing/pi.aspx?id=o>. Accessed July 2018.
2. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. MMWR Recomm Rep 2016;65(No. RR-1):1–49. DOI: <http://dx.doi.org/10.15585/mmwr.rr6501e1>.

Reviews, Revisions, and Approvals	Date	Approval Date
New policy	07/18	07/18
Modified initial criteria to require trial of 1 preferred long-acting opiate.	10/18	10/18

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of

CLINICAL POLICY

Oxycodone



insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright

CLINICAL POLICY

Oxycodone



or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.